ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
MD Anderson Cancer Center at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
MD Anderson Cancer Center takes part in 59 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8006. Its program focuses on molecularly guided treatment and emerging therapies across cancers. Specific topics include KRAS G12D-targeted treatment for pancreatic cancer and using circulating tumour DNA to track treatment response and residual disease.
| Organization | ESMO 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, TX | |
Comprehensive cancer treatment and research centre of the University of Texas in Houston, Texas. | Booth Exhibiting at Booth 8006 Poster Fri Oct 23 13:00–15:00 A phase 2 study of emiltatug ledadotin (Emi-Le) in patients with aggressive adenoid cystic carcinoma: EMBLEM-1 Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 AI-informed novel biomarker discovery for BRAF + EGFR + PD-1 therapies in MSS, BRAFV600E metastatic colorectal cancer (mCRC) Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Cisplatin or carboplatin? A quantitative umbrella review of meta-analyses in solid tumors to inform treatment choice Gynaecological cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Delineating the targetable transcriptome in cancers of unknown primary (CUP) for antibody-drug conjugates (ADC) Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Integrated analysis of tissue, plasma and PBMCs in triple negative inflammatory breast cancer patients by response to KEYNOTE-522 regimen Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Long-term results of ASP-1929 photoimmunotherapy (PIT) with pembrolizumab (PEM) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Phase 1/2 study of the novel werner helicase inhibitor EIK1005 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including MSI-H or dMMR tumors Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Preclinical evaluation of CD70-directed antibody-radionuclide conjugate platform for the management of clear cell renal cell carcinoma Haematological malignanciesGenitourinary cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Talk Fri Oct 23 14:30–14:45 Abstract Fri Oct 23 14:32–14:37 702RO - Immune checkpoint blockade for patients with leptomeningeal metastases from non-small cell lung cancer Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Analysis of the safety, tolerability, and PK of EIK1005, a novel WRN inhibitor Gastrointestinal cancers Poster Fri Oct 23 15:15–16:00 Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Evaluation of ctDNA minimal residual disease (MRD) testing to complement radiographic surveillance in patients (Pts) with colorectal cancer (CRC): Results from the MD Anderson (MDA) INTERCEPT program Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 First-in-human trial of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor, in MTAP-deficient advanced tumors Gastrointestinal cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers Poster Fri Oct 23 15:15–16:00 Goblet cell appendiceal adenocarcinoma is a distinct disease entity defined by LGR5/Wnt mediated oncogenesis driving an immune-excluded tumor microenvironment Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Prevalence, prognosis, and impact on tumor microenvironment (TME) of homozygous MTAP deletion (MTAP-del) in advanced solid tumors Gastrointestinal cancersLung & thoracic cancersGenitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Safety and activity of IAM1363, a CNS penetrant HER2 TKI in participants with HER2 altered advanced cancers Gastrointestinal cancersGynaecological cancersBreast cancerSarcoma, CNS, head & neck and rare cancersGenitourinary cancers Poster Fri Oct 23 15:15–16:00 Chair Fri Oct 23 16:15–17:45 Emerging therapeutic strategies in advanced prostate cancer Genitourinary cancers Abstract Fri Oct 23 16:47–16:52 Talk Fri Oct 23 17:15–17:35 New targets (ADCs, new biologies) Genitourinary cancers Satellite Fri Oct 23 18:45–19:10 Elacestrant in ESR1-mutant mBC: Establishing the Standard of Care Breast cancerBiomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Abstract Sat Oct 24 08:35–08:40 Abstract Sat Oct 24 08:45–09:00 Invited Discussant LBA73, 2719RO and 2700RO Lung & thoracic cancers Talk Sat Oct 24 09:10–09:30 Poster Sat Oct 24 12:00–12:45 A phase 2 study of neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): Final analysis Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 RNA-seq phasing spotlights secondary oncogenic mutations for clinical interpretation Biomarkers & precision oncology Satellite Sat Oct 24 13:05–13:25 KRAS G12C Biology: A Unique Oncogenic Driver With Dual Impact Lung & thoracic cancers Satellite Sat Oct 24 14:00–14:15 A new chapter? The evolving role of ADCs in mCRC Gastrointestinal cancers Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 15:05–15:15 Abstract Sat Oct 24 15:15–15:27 Chair Sat Oct 24 16:30–18:00 Updates on myeloid neoplasms with a focus on medical oncology practice Haematological malignancies Talk Sat Oct 24 17:10–17:30 Current treatment landscape of AML based on a comprehensive genomic assessment Haematological malignancies Abstract Sun Oct 25 08:30–08:35 Abstract Sun Oct 25 08:30–08:35 4244RO - NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial Biomarkers & precision oncology Abstract Sun Oct 25 09:19–09:24 Talk Sun Oct 25 10:45–11:00 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Allele specific characteristics of KRASQ61 mutated gastrointestinal malignancies with clinical outcomes and transcriptomic features in pancreatic cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Chromosomal instability is associated with worse survival and an immunosuppressive tumor microenvironment in microsatellite stable colorectal cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Organ-specific response to KRAS inhibitors in metastatic colorectal cancer Gastrointestinal cancers Poster Sun Oct 25 12:00–12:45 Overall survival in young- vs average-onset metastatic colorectal cancer across actionable molecular subgroups: A 4,717-patient hierarchical analysis at MD Anderson Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:10–13:25 Emerging evidence in BRAFV600E-mutant mCRC Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 15:15–15:25 Talk Sun Oct 25 15:30–15:50 Pathological response for the win Melanoma & skin cancers Abstract Sun Oct 25 16:30–16:42 LBA5 - Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC Lung & thoracic cancersGastrointestinal cancers Chair Sun Oct 25 16:30–18:00 Rapid oral: Supportive and palliative care Nursing & supportive care Abstract Sun Oct 25 16:45–16:55 Invited Discussant 3469RO, 3085RO and 3895RO Nursing & supportive care Chair Mon Oct 26 08:30–10:00 Chair Mon Oct 26 08:30–10:00 Proffered paper: Supportive and palliative care Nursing & supportive care Chair Mon Oct 26 08:30–10:00 Talk Mon Oct 26 09:15–09:30 Abstract Mon Oct 26 09:24–09:36 Talk Mon Oct 26 10:35–10:55 Biology and mechanisms of action of novel immunotherapies Lung & thoracic cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 AXL protein expression by immunohistochemistry in sarcoma subtypes: Implications for antibody-drug conjugate development Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Clinical prediction model for early mortality in leukemia patients following inpatient chemotherapy Haematological malignancies Poster Mon Oct 26 12:00–12:45 Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLC Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Neoadjuvant and adjuvant tiragolumab plus atezolizumab in PD-L1-positive oral cavity squamous cell carcinoma Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Satellite Mon Oct 26 13:05–13:25 Charting the Path Forward in KRAS G12C Lung Cancer Lung & thoracic cancers Talk Mon Oct 26 14:45–15:00 Chair Mon Oct 26 14:45–16:15 Chair Mon Oct 26 14:45–16:15 Abstract Mon Oct 26 15:39–15:44 Abstract Mon Oct 26 15:44–15:56 Talk Mon Oct 26 16:30–16:45 IO-based systemic therapy (incl pt selection) Sarcoma, CNS, head & neck and rare cancers Satellite Mon Oct 26 19:25–19:50 Managing Complexity: Sequencing HER2-Directed Therapies After Progression Lung & thoracic cancersBiomarkers & precision oncology |
Find decision makers at MD Anderson Cancer Center
Tell us what you sell and we’ll find the people at MD Anderson Cancer Center most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction